Synthetic cannabinoids

FAB-144

Summary FAB-144, classified as an indazole-derived synthetic cannabinoid, is believed to exhibit vigorous agonistic activity towards the CB1 receptor. This compound has gained notoriety for its online availability as a designer drug and is the indazole counterpart of XLR-11. Identifiers IUPAC name CAS Number 2180935-79-7  PubChem CID 102135350 ChemSpider 32055552 UNII B9JT6F9X8V Chemical and physical …

FAB-144 Read More »

CUMYL-THPINACA

Summary CUMYL-THPINACA also recognized as SGT-42, is categorized as an indazole-3-carboxamide-based synthetic cannabinoid. This compound is a robust agonist for cannabinoid receptors, exhibiting approximately 6 times greater selectivity for CB1. Specifically, it boasts an EC50 of 0.1nM for human CB1 receptors and 0.59nM for human CB2 receptors. Identifiers IUPAC name CAS Number 1400742-50-8  PubChem CID …

CUMYL-THPINACA Read More »

CUMYL-PINACA

Summary CUMYL-PINACA also referred to as SGT-24, belongs to the class of indazole-3-carboxamide synthetic cannabinoids. It is a robust agonist for cannabinoid receptors, demonstrating about threefold selectivity for CB1. Its affinity for human CB1 receptors is notably high, with an EC50 of 0.15nM, and it exhibits a similar potency for human CB2 receptors, with an …

CUMYL-PINACA Read More »

CUMYL-4CN-BINACA

Summary CUMYL-4CN-BINACA, also known as CUMYL-CYBINACA or SGT-78, is an indazole-3-carboxamide-based synthetic cannabinoid that has been distributed online as a designer drug. This compound acts as a potent agonist for CB1 and CB2 cannabinoid receptors, with EC50 values of 0.58 nM and 6.12 nM, respectively, as demonstrated in in vitro studies.In animal models, CUMYL-4CN-BINACA has …

CUMYL-4CN-BINACA Read More »

APP-FUBINACA

Summary APP-FUBINACA is a synthetic cannabinoid based on the indazole structure, and it has been distributed online as a designer drug. Regarding its pharmacological profile, research has indicated that APP-FUBINACA exhibits only moderate binding affinity for the CB1 receptor, with a Ki value of 708 nM. However, specific data regarding its EC50 has yet to …

APP-FUBINACA Read More »

APINACA

Summary APINACA, also known as AKB48 or N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide, is a substance that functions as a reasonably potent agonist for cannabinoid receptors. It exhibits full agonist activity at the CB1 receptor, with an EC50 of 142 nM and a Ki of 3.24 nM. To provide context, this Ki value is notably lower than that of Δ9-THC …

APINACA Read More »

AMB-CHMINACA

Summary AMB-CHMINACA, alternatively known as MMB-CHMINACA or MA-CHMINACA, belongs to the family of indazole-based synthetic cannabinoids. Notably, it exhibits strong agonistic activity towards the CB1 receptor and has entered the online market as a designer drug. Identifiers IUPAC name CAS Number 1863066-03-8(racemate) PubChem CID 119026010 ChemSpider 32055578 UNII OU56JJP891Y21A13WADY(racemate) Chemical and physical data Formula C21H29N3O3 …

AMB-CHMINACA Read More »

ADSB-FUB-187

Summary ADSB-FUB-187, an indazole-based synthetic cannabinoid, exhibits remarkable potency as a CB1 receptor agonist, boasting an impressively low binding affinity with a Ki value of 0.09 nM and an EC50 of 1.09 nM. Pfizer’s 2009 patent, WO 2009/106982, introduced this compound as example 187. While it stands out as the most tightly binding substance within …

ADSB-FUB-187 Read More »

ADB-PINACA

Summary ADB-PINACA, a cannabinoid designer drug, finds its place as a constituent in certain synthetic cannabis products. It stands out as a robust agonist of both the CB1 and CB2 receptors, boasting impressive EC50 values of 0.52 nM and 0.88 nM, respectively. Notably, akin to MDMB-FUBINACA, this compound incorporates a tert-leucine amino acid residue Identifiers …

ADB-PINACA Read More »

ADB-FUBINACA

Summary ADB-FUBINACA, a synthetic designer drug, initially surfaced in synthetic cannabis mixtures in Japan back in 2013. Notably, by 2018, it had risen to become the third most frequently detected synthetic cannabinoid in drug seizures by the Drug Enforcement Administration.The (S)-enantiomer of ADB-FUBINACA was detailed in a Pfizer patent dating back to 2009. This enantiomer …

ADB-FUBINACA Read More »